Clinical value of neoadjuvant chemotherapy combined with cytoreductive surgery and intraperitoneal hyperthermia in advanced ovarian cancer
10.3760/cma.j.issn.1008-6706.2019.15.017
- VernacularTitle: 新辅助化疗联合肿瘤细胞减灭术及腹腔热灌注治疗晚期卵巢癌的价值分析
- Author:
Bingxiu ZHOU
1
;
Jianying DU
;
Yinchuan LIU
Author Information
1. Department of Gynaecology, the Maternal and Child Health Care Hospital of Weihai, Weihai, Shandong 264200, China
- Publication Type:Journal Article
- Keywords:
Oophoroma neoplasms;
Chemotherapy, adjuvant;
Gynecological Surgery procedures;
Chemotherapy, cancer, regional perfusion;
Diathermy
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(15):1858-1861
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy of neoadjuvant chemotherapy combined with cytoreductive surgery and intraperitoneal hyperthermia in the treatment of advanced ovarian cancer.
Methods:From June 2014 to April 2017, 72 patients with advanced ovarian cancer who were treated in the Maternal and Child Health Care Hospital of Weihai were selected as the research subjects.According to the digital table method, the patients were randomly divided into two groups, with 36 cases in each group.The control group was treated with neoadjuvant chemotherapy combined with cytoreductive surgery.The observation group was treated with neoadjuvant chemotherapy combined with cytoreductive surgery and intraperitoneal hyperthermic perfusion.After 3 months of chemotherapy, the curative effect was statistically analyzed.
Results:The operation time, the amount of ascites and the amount of bleeding in the observation group were significantly less than those in the control group (all P<0.05). There were no statistically significant differences in surgical incision stage I healing rate and the rate of pelvic infection between the two groups (P>0.05). After treatment, the remission rate in the control group was 55.5%(20/36), which was significantly lower than 77.8%(28/36) in the observation group (χ2=4.92, P<0.05). All patients were followed up for 1 year.The recurrence rate of the control group was 33.3%, which was significantly higher than 22.2% of the observation group (χ2=5.71, P<0.05).
Conclusion:Neoadjuvant chemotherapy combined with cytoreductive surgery and intraperitoneal hyperthermia in the treatment of advanced ovarian cancer is effective and worthy of clinical application.
